ALT5 Sigma (NASDAQ:ALTS) Earns Sell (E+) Rating from Weiss Ratings

ALT5 Sigma (NASDAQ:ALTS)‘s stock had its “sell (e+)” rating restated by investment analysts at Weiss Ratings in a research report issued on Thursday,Weiss Ratings reports.

Separately, Wall Street Zen downgraded shares of ALT5 Sigma from a “hold” rating to a “strong sell” rating in a report on Saturday, August 16th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

ALT5 Sigma Stock Performance

NASDAQ:ALTS opened at $2.52 on Thursday. ALT5 Sigma has a 1-year low of $1.80 and a 1-year high of $10.95. The company’s fifty day moving average price is $3.62 and its 200-day moving average price is $6.06. The company has a current ratio of 0.88, a quick ratio of 0.88 and a debt-to-equity ratio of 1.45.

Insider Transactions at ALT5 Sigma

In related news, Director David C. Danziger acquired 10,000 shares of the firm’s stock in a transaction on Thursday, August 14th. The shares were acquired at an average cost of $7.30 per share, with a total value of $73,000.00. Following the completion of the acquisition, the director directly owned 20,000 shares in the company, valued at approximately $146,000. This trade represents a 100.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.65% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ALT5 Sigma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. First Citizens Bank & Trust Co. purchased a new position in ALT5 Sigma during the third quarter valued at $35,000. Arkadios Wealth Advisors acquired a new stake in shares of ALT5 Sigma in the third quarter valued at about $62,000. Evernest Financial Advisors LLC acquired a new stake in shares of ALT5 Sigma in the second quarter valued at about $87,000. Bridgeway Capital Management LLC raised its position in shares of ALT5 Sigma by 9.4% in the second quarter. Bridgeway Capital Management LLC now owns 19,339 shares of the company’s stock valued at $140,000 after buying an additional 1,661 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of ALT5 Sigma in the second quarter valued at about $380,000. 6.27% of the stock is owned by hedge funds and other institutional investors.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments.